×
About 2,373 results

ALLMedicine™ Chronic Urticaria Center

Research & Reviews  537 results

Are antihistamines still used during omalizumab treatment for chronic spontaneous urtic...
https://doi.org/10.1684/ejd.2022.4334
European Journal of Dermatology : EJD; Melé-Ninot G, Serra-Baldrich E et. al.

Dec 6th, 2022 - The guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend adding omalizumab to the treatment of patients with uncontrolled disease despite four-fold doses of second-generation antihistamines (AH). On the contrary, some stud...

Exploration of the Efficacy of Anti-Immunoglobulin E Monoclonal Antibodies in the Treat...
https://doi.org/10.1111/imm.13613
Immunology Qian XJ, Hu XT et. al.

Nov 26th, 2022 - The present study aims to evaluate the efficacy of an anti-immunoglobulin E monoclonal antibody (omalizumab) in the treatment of allergic asthma (AS). A total of 34 patients with moderate-to-severe bronchial asthma admitted to the Respiratory Depa...

Management of Allergic Skin Disorders in Pregnancy.
https://doi.org/10.1016/j.iac.2022.05.012
Immunology and Allergy Clinics of North America; Pope EM, Laageide L et. al.

Nov 22nd, 2022 - The safe management of allergic skin disorders during pregnancy is essential to maternal and fetal health. Poorly controlled allergic skin disease affects the health of mother and child. This article reviews the disease course and treatment of ato...

Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis ...
https://doi.org/10.1016/j.iac.2022.07.001
Immunology and Allergy Clinics of North America; L Ramos C, Namazy J

Nov 22nd, 2022 - Asthma, allergic rhinitis, chronic urticaria, and atopic dermatitis are common diseases that affect hundreds of thousands of pregnant women each year. The authors discuss the use of biologics in women who are pregnant or lactating, indications, av...

Artemisinic acid attenuated symptoms of substance P-induced chronic urticaria in a mice...
https://doi.org/10.1016/j.intimp.2022.109437
International Immunopharmacology; Ding Y, Dang B et. al.

Nov 21st, 2022 - Chronic urticaria (CU) is a common skin disease that affects about 1% of the world's population of all ages and seriously affects patients' quality of life. Therefore, further safe and effective treatments are urgently needed. Therefore, artemisin...

see more →

Drugs  265 results see all →

Clinicaltrials.gov  65 results

The Association Between Human Microbiome and Vitamin D in Chronic Urticaria
https://clinicaltrials.gov/ct2/show/NCT05497596

Sep 1st, 2022 - Urticaria is a chronic allergic inflammatory disorder. Genetic and environmental factors, such as exposure to allergens and microbes, have a detrimental role in the development of chronic urticaria. Vitamin D also has an important role in urticari...

Positive Psychotherapy-Based Counseling (PPT)
https://clinicaltrials.gov/ct2/show/NCT05513079

Aug 26th, 2022 - Chronic urticaria is a condition that impairs the patient's quality of life, interferes with routine daily activities, and is often associated with anxiety. It constitutes a significant burden associated with psychiatric comorbidities such as Fund...

The Role of the Coagulation Pathways in Recurrent Angioedema
https://clinicaltrials.gov/ct2/show/NCT02892682

Aug 25th, 2022 - Previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema. This study aim to compare groups with isolated wheals, isolated angioedema, combination of bo...

Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
https://clinicaltrials.gov/ct2/show/NCT04513548

Jul 28th, 2022 - There are 58 patients out of 68 participants (10 are Healthy Volunteers)

Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria.
https://clinicaltrials.gov/ct2/show/NCT03443362

Jul 19th, 2022 - Chronic urticaria (CU) is an inflammatory skin disease that is defined by the presence of urticaria (hives), on most days of the week, for a period of six weeks or longer. About 40 percent of patients with CU have accompanying episodes of angioede...

see more →

News  81 results

Doctors Can Combat Urticaria Misinformation With Empathy and Facts
https://www.medscape.com/viewarticle/984393

Nov 21st, 2022 - Patients suffering from chronic urticaria can easily find bogus causes and treatments online, and providers need to refute the falsehoods with facts, a research letter suggests. "Chronic urticaria can have a major psychological impact, leaving pat...

Chronic Urticaria During Pregnancy: Study Analyzes Outcomes, Treatments
https://www.medscape.com/viewarticle/982304

Oct 12th, 2022 - Most patients with chronic urticaria (CU) used treatment during pregnancy, especially with second-generation antihistamines, which appear to be safe regardless of the trimester. In addition, the rates of preterm births and medical problems of newb...

How do patients with chronic urticaria fare during pregnancy?
https://www.mdedge.com/dermatology/article/258561/medical-dermatology/how-do-patients-chronic-urticaria-fare-during
Doug Brunk

Oct 11th, 2022 - Most patients with chronic urticaria (CU) used treatment during pregnancy, especially with second-generation antihistamines, which appear to be safe regardless of the trimester. In addition, the rates of preterm births and medical problems of newb.

Targeted Anti-IgE Therapy Found Safe and Effective for Chronic Urticaria
https://www.medscape.com/viewarticle/980846

Sep 15th, 2022 - MILAN – The therapeutic value of inhibiting the activity of IgE in patients with chronic spontaneous urticaria (CSU) was reinforced by two large phase 3 trials with ligelizumab, a drug characterized as a new generation anti-IgE monoclonal antibody...

Targeted anti-IgE therapy found safe and effective for chronic urticaria
https://www.mdedge.com/dermatology/article/257859/mixed-topics/targeted-anti-ige-therapy-found-safe-and-effective-chronic
Ted Bosworth

Sep 14th, 2022 - MILAN – The therapeutic value of inhibiting the activity of IgE in patients with chronic spontaneous urticaria (CSU) was reinforced by two large phase 3 trials with ligelizumab, a drug characterized as a new generation anti-IgE monoclonal antibody.

see more →

Patient Education  1 results see all →